

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Claims

1 A compound according to formula (I)



(I)

wherein:

5 n is 1, 2, 3 or 4;

R^1 is selected from

- a. an optionally substituted straight chain or branched chain C_{1-6} alkyl group,
- b. an optionally substituted straight chain or branched chain C_{2-6} alkenyl group,
- c. an optionally substituted straight chain or branched chain C_{2-6} alkynyl group,
- 10 d. Aryl,
- e. Aromatic heterocycle,
- f. Heterocycle, and
- g. hydrogen;

where the optional substituents in groups (a), (b) and (c) above are selected from: C_3 - C_7 cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR^9 , NR^9R^{10} , $S(O)_pR^9$, $OC(O)R^{10}$, CO_2R^9 , $CONR^9R^{10}$, $SO_2NR^9R^{10}$, halo and $NHSO_2R^9$, and where p is 0, 1 or 2;

R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl optionally substituted by OR^9 or halo;

R^9 and R^{10} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl;

Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R^{11} , halo, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{11}$, CO_2R^{12} , $NR^{12}SO_2R^{11}$, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$, where R^{11} is straight chain or branched chain C_{1-6} alkyl and R^{12} and R^{13} are each independently selected from hydrogen and straight chain or branched chain C_{1-6} alkyl;


Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally substituted with one or more groups selected from OR^{12} , $NR^{12}R^{13}$, CO_2R^{12} , $NR^{12}CO_2R^{11}$, R^{11} ,

halo, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $NR^{12}SO_2R^{11}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$; and

Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR^{12} , $NR^{12}R^{13}$, CO_2R^{12} , $NR^{12}CO_2R^{13}$, R^{11} , halo, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $NR^{12}SO_2R^{11}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$,


or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of said compound or said tautomer.

2 A compound according to claim 1 wherein the substitution pattern of the imidazole is as depicted in formula (ID¹)



(ID¹)

3 A compound according to Claim 1 wherein the stereochemistry is as depicted in formula (IA)



(IA)

15

4 A compound according to any preceding Claim wherein n is 2 or 3.

5 A compound according to Claim 4 wherein n is 2.

6 A compound according to any preceding Claim wherein R¹ is hydrogen, Aryl or C₁₋₆ alkyl optionally substituted by C₃₋₇ cycloalkyl or Aryl.

7 A compound according to Claim 6 wherein R¹ is hydrogen, Aryl or C₁₋₆ alkyl optionally substituted by cyclohexyl or Aryl.

8 A compound according to Claim 7 wherein R¹ is hydrogen, phenyl, C₁₋₅ alkyl or C₁₋₃ alkyl substituted by cyclohexyl or phenyl.

5 9 A compound according to Claim 7 wherein R¹ is hydrogen, Aryl or propyl.

10 A compound according to Claim 8 or Claim 9 wherein R¹ is propyl.

11 A compound according to any preceding Claim wherein R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen or C₁₋₃ alkyl.

12 A compound according to Claim 11 wherein R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are all hydrogen.

13 A compound according to Claim 1, selected from:

(+)-(2S)-2-[(3S)-3-aminopyrrolidinyl]-3-(1*H*-imidazol-4-yl)propanoic acid;

(+)-(2S)-2-[(3S)-3-aminopyrrolidinyl]-3-(1-propyl-1*H*-imidazol-4-yl)propanoic acid;

(2S)-2-[(3S)-3-aminopyrrolidinyl]-3-(1-isopentyl-1*H*-imidazol-4-yl)propanoic acid;

15 (+)-(2S)-2-[(3S)-3-aminopyrrolidinyl]-3-[1-(2-cyclohexylethyl)-1*H*-imidazol-4-yl]propanoic acid;

(+)-(2S)-2-[(3S)-3-aminopyrrolidinyl]-3-[1-(2-phenylethyl)-1*H*-imidazol-4-yl]propanoic acid; and

(+)-(2S)-2-[(3S)-3-aminopyrrolidinyl]-3-[1-phenyl-1*H*-imidazol-4-yl]propanoic acid,

20 and pharmaceutically acceptable salts thereof.

14 A compound according to any of Claims 1 to 12 for use as a medicament.

15 A compound according to any of Claims 1 to 12 for use as a medicament for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

16 A pharmaceutical composition comprising a compound according to any of Claims 1 to 13 and a pharmaceutically acceptable carrier.


17 The use of a compound according to any of Claims 1 to 13 for the preparation of a medicament for the treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

18 A use according to Claim 17 wherein the medicament is for the treatment of a thrombotic condition.

19 A method of treatment of a condition selected from thrombotic conditions, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels

in the body, comprising administration of a compound according to any of Claims 1 to 13 to a subject in need of such treatment.

20 A process for the preparation of a compound according to formula (I)



(I)

5 wherein:

n is 1, 2, 3 or 4;

R¹ is selected from

- a. an optionally substituted straight chain or branched chain C₁₋₆ alkyl group,
- b. an optionally substituted straight chain or branched chain C₂₋₆ alkenyl group,
- 10 c. an optionally substituted straight chain or branched chain C₂₋₆ alkynyl group,
- d. Aryl,
- e. Aromatic heterocycle,
- f. Heterocycle, and
- g. hydrogen;

15 where the optional substituents in groups (a), (b) and (c) above are selected from: C₃₋₇ cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR⁹, NR⁹R¹⁰, S(O)_pR⁹, OC(O)R¹⁰, CO₂R⁹, CONR⁹R¹⁰, SO₂NR⁹R¹⁰, halo and NHSO₂R⁹, and where p is 0, 1 or 2;

R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl optionally substituted by OR⁹ or halo;

20 R⁹ and R¹⁰ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl;

Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R¹¹, halo, OR¹², NR¹²R¹³, NR¹²CO₂R¹¹, CO₂R¹², NR¹²SO₂R¹¹, CN, haloalkyl, O(haloalkyl), SR¹², S(O)R¹¹, SO₂R¹¹,
25 OC(O)R¹², SO₂NR¹²R¹³ and C(O)NR¹²R¹³, where R¹¹ is straight chain or branched chain C₁₋₆ alkyl and R¹² and R¹³ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl;


Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally

substituted with one or more groups selected from OR^{12} , $NR^{12}R^{13}$, CO_2R^{12} , $NR^{12}CO_2R^{11}$, R^{11} , halo, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $NR^{12}SO_2R^{11}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$; and

Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said ring further being optionally substituted with one or more groups selected from OR^{12} , $NR^{12}R^{13}$, CO_2R^{12} , $NR^{12}CO_2R^{13}$, R^{11} , halo, CN, haloalkyl, O(haloalkyl), SR^{12} , $S(O)R^{11}$, SO_2R^{11} , $OC(O)R^{12}$, $NR^{12}SO_2R^{11}$, $SO_2NR^{12}R^{13}$ and $C(O)NR^{12}R^{13}$,

or a tautomer thereof, comprising the steps of:

(i) preparing a compound according to formula (II)



(II)


wherein:

P^1 is an optionally substituted C_{1-6} alkyl group, an optionally substituted C_{4-7} cycloalkyl group, an optionally substituted benzyl group or a tri(C_{1-6} alkyl)silyl group; and

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and n are as defined for formula (I); and

(ii) treating said compound of formula (II) with a reagent or combination of reagents suitable for removing the P^1 group.

21 A process for the preparation of a compound according to formula (I)



(I)

wherein:

n is 1, 2, 3 or 4;

R¹ is selected from

- 5 a. an optionally substituted straight chain or branched chain C₁₋₆ alkyl group,
 b. an optionally substituted straight chain or branched chain C₂₋₆ alkenyl group,
 c. an optionally substituted straight chain or branched chain C₂₋₆ alkynyl group,
 d. Aryl,
 e. Aromatic heterocycle,
 f. Heterocycle, and
 g. hydrogen;

10 where the optional substituents in groups (a), (b) and (c) above are selected from: C₃₋₇ cycloalkyl, Aryl, Aromatic heterocycle, Heterocycle, OR⁹, NR⁹R¹⁰, S(O)_pR⁹, OC(O)R¹⁰, CO₂R⁹, CONR⁹R¹⁰, SO₂NR⁹R¹⁰, halo and NHSO₂R⁹, and where p is 0, 1 or 2;

R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl optionally substituted by OR⁹ or halo;

R⁸ is hydrogen;

15 R⁹ and R¹⁰ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl;


 Aryl is a 6-14 membered aromatic monocyclic or fused polycyclic carbocyclic group optionally substituted with one or more groups selected from R¹¹, halo, OR¹², NR¹²R¹³, NR¹²CO₂R¹¹, CO₂R¹², NR¹²SO₂R¹¹, CN, haloalkyl, O(haloalkyl), SR¹², S(O)R¹¹, SO₂R¹¹,
20 OC(O)R¹², SO₂NR¹²R¹³ and C(O)NR¹²R¹³, where R¹¹ is straight chain or branched chain C₁₋₆ alkyl and R¹² and R¹³ are each independently selected from hydrogen and straight chain or branched chain C₁₋₆ alkyl;

 Aromatic heterocycle is a 5 to 7 membered aromatic ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being optionally
25 substituted with one or more groups selected from OR¹², NR¹²R¹³, CO₂R¹², NR¹²CO₂R¹¹, R¹¹, halo, CN, haloalkyl, O(haloalkyl), SR¹², S(O)R¹¹, SO₂R¹¹, OC(O)R¹², NR¹²SO₂R¹¹, SO₂NR¹²R¹³ and C(O)NR¹²R¹³; and

 Heterocycle is a 3 to 8 membered ring containing from 1 to 3 heteroatoms, each independently selected from O, S and N, said ring being saturated or partially saturated, said
30 ring further being optionally substituted with one or more groups selected from OR¹², NR¹²R¹³, CO₂R¹², NR¹²CO₂R¹³, R¹¹, halo, CN, haloalkyl, O(haloalkyl), SR¹², S(O)R¹¹, SO₂R¹¹, OC(O)R¹², NR¹²SO₂R¹¹, SO₂NR¹²R¹³ and C(O)NR¹²R¹³,

or a tautomer thereof, comprising the steps of:

- (i) preparing a compound according to formula (IV)



(IV)

wherein:

P² is an (optionally substituted C₁₋₆ alkyl)oxycarbonyl group, an (optionally substituted C₄₋₇ cycloalkyl)oxycarbonyl group, an (optionally substituted benzyl)oxycarbonyl group or an
5 (optionally substituted fluorenylmethyl)oxycarbonyl group; and

R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and n are as defined for formula (I); and

(ii) treating said compound of formula (II) with a reagent or combination of reagents suitable for removing the P² group.